| FAMI 0.1501 26.45% | GPRO 1.69 37.40% | RITR 0.0987 11.90% | NVDA 224.41 3.21% | NVD 3.79 -6.42% | MGN 0.13 8.70% | PCG 13.33 -5.19% | GPUS 0.1984 -17.09% | LHAI 1.1 34.02% | TSLL 9.37 0.43% | NU 15.4 6.50% | ONDS 7.61 8.10% | VIVK 0.9011 14.95% | PPBT 1.98 19.28% | EOSE 3.61 18.75% | NIO 3.855 -4.93% | BITO 10.4 0.24% | INTC 90.05 1.21% | PATH 17.99 -0.83% | GELS 0.7 31.58% | F 14.15 2.24% | CNH 13.65 9.20% | RIG 6.22 5.07% | HPE 51.855 1.94% | AAL 13.11 1.24% | VIOT 1.78 83.64% | SPCX 140.71 -1.07% | NOK 9.84 -0.91% | BTAI 0.107 -21.90% | BBD 3.45 3.92% | BIAF 9.75 47.95% | SOXL 106.35 0.42% | SOXS 51.83 -0.75% | SOFI 17.84 4.63% | PLUG 2.09 0.00% | IREN 39.6 7.55% | EWZ 38.09 4.16% | PLTR 169.46 -5.81% | PFE 29.02 1.65% | TQQQ 69.6 0.65% | NCPL 1.03 30.05% | DELL 492 15.76% | CDE 21.42 6.04% | HYG 79.11 0.01% | TSLA 357.01 0.26% | T 25.96 -0.15% | AAPL 324.96 -0.05% | SQQQ 39.71 -0.65% | SMCI 37 0.79% | XLF 57.66 0.80%

Barclays Downgrades Medpace To Underweight, Cites Valuation Concerns

Barclays downgraded Medpace Holdings Inc. (NASDAQ: MEDP) from Equalweight to Underweight and reduced its price target to $425.00 from $450.00.

The firm said the downgrade was primarily valuation-driven, noting that Medpace shares were trading well above the premium historically enjoyed relative to peers. While the biotech market was described as “bouncing along the bottom,” Barclays said it expected the company to continue winning new business.

However, the firm flagged potential risk in the second half of 2026, citing concern over whether Medpace could fill its backlog with faster-burning projects to sustain elevated growth as more traditional work ramps.

Published on: October 2, 2025